Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline

Hiromasa Inoue, Masashi Komori, Takafumi Matsumoto, Satoru Fukuyama, Mikiko Matsumura, Takako Nakano, Miyuki Tsuda, Koichiro Matsumoto, Akiko Kanaya, Atsushi Moriwaki, Hisamichi Aizawa, Makoto Yoshida, Yoichi Nakanishi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Patients with severe asthma require multiple therapies to improve lung function and reduce symptoms. The use of long-acting inhaled β2-agonists plus theophylline in addition to high doses of inhaled corticosteroids (ICSs) for the treatment of severe asthma has not been extensively studied. Objective: The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma. Methods: We undertook a randomized, placebo-controlled, crossover study to compare the effect of a single dose of inhaled salmeterol (50 μg) or a placebo in patients with severe asthma whose conditions were not being adequately controlled by therapies with high-dose ICSs plus oral theophylline with or without leukotriene receptor antagonists. Results: Twenty patients took part in the trial. Compared with the placebo, the inhalation of salmeterol significantly increased the FEV1. Even in the 9 patients treated with high-dose ICSs plus theophylline plus a leukotriene receptor antagonist, the FEV1 increased significantly more after salmeterol than after the placebo. Conclusion: Patients with severe asthma receiving high-dose ICSs plus theophylline may benefit from the addition of salmeterol.

Original languageEnglish
Pages (from-to)611-616
Number of pages6
JournalRespiration
Volume74
Issue number6
DOIs
Publication statusPublished - Nov 1 2007

Fingerprint

Theophylline
Adrenal Cortex Hormones
Asthma
Placebos
Leukotriene Antagonists
Cross-Over Studies
Inhalation
Therapeutics
Salmeterol Xinafoate
Safety
Lung

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Inoue, H., Komori, M., Matsumoto, T., Fukuyama, S., Matsumura, M., Nakano, T., ... Nakanishi, Y. (2007). Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. Respiration, 74(6), 611-616. https://doi.org/10.1159/000095678

Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. / Inoue, Hiromasa; Komori, Masashi; Matsumoto, Takafumi; Fukuyama, Satoru; Matsumura, Mikiko; Nakano, Takako; Tsuda, Miyuki; Matsumoto, Koichiro; Kanaya, Akiko; Moriwaki, Atsushi; Aizawa, Hisamichi; Yoshida, Makoto; Nakanishi, Yoichi.

In: Respiration, Vol. 74, No. 6, 01.11.2007, p. 611-616.

Research output: Contribution to journalArticle

Inoue, H, Komori, M, Matsumoto, T, Fukuyama, S, Matsumura, M, Nakano, T, Tsuda, M, Matsumoto, K, Kanaya, A, Moriwaki, A, Aizawa, H, Yoshida, M & Nakanishi, Y 2007, 'Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline', Respiration, vol. 74, no. 6, pp. 611-616. https://doi.org/10.1159/000095678
Inoue, Hiromasa ; Komori, Masashi ; Matsumoto, Takafumi ; Fukuyama, Satoru ; Matsumura, Mikiko ; Nakano, Takako ; Tsuda, Miyuki ; Matsumoto, Koichiro ; Kanaya, Akiko ; Moriwaki, Atsushi ; Aizawa, Hisamichi ; Yoshida, Makoto ; Nakanishi, Yoichi. / Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. In: Respiration. 2007 ; Vol. 74, No. 6. pp. 611-616.
@article{43347c957e62426b8977a30eaf74bb1d,
title = "Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline",
abstract = "Background: Patients with severe asthma require multiple therapies to improve lung function and reduce symptoms. The use of long-acting inhaled β2-agonists plus theophylline in addition to high doses of inhaled corticosteroids (ICSs) for the treatment of severe asthma has not been extensively studied. Objective: The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma. Methods: We undertook a randomized, placebo-controlled, crossover study to compare the effect of a single dose of inhaled salmeterol (50 μg) or a placebo in patients with severe asthma whose conditions were not being adequately controlled by therapies with high-dose ICSs plus oral theophylline with or without leukotriene receptor antagonists. Results: Twenty patients took part in the trial. Compared with the placebo, the inhalation of salmeterol significantly increased the FEV1. Even in the 9 patients treated with high-dose ICSs plus theophylline plus a leukotriene receptor antagonist, the FEV1 increased significantly more after salmeterol than after the placebo. Conclusion: Patients with severe asthma receiving high-dose ICSs plus theophylline may benefit from the addition of salmeterol.",
author = "Hiromasa Inoue and Masashi Komori and Takafumi Matsumoto and Satoru Fukuyama and Mikiko Matsumura and Takako Nakano and Miyuki Tsuda and Koichiro Matsumoto and Akiko Kanaya and Atsushi Moriwaki and Hisamichi Aizawa and Makoto Yoshida and Yoichi Nakanishi",
year = "2007",
month = "11",
day = "1",
doi = "10.1159/000095678",
language = "English",
volume = "74",
pages = "611--616",
journal = "Respiration; international review of thoracic diseases",
issn = "0025-7931",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline

AU - Inoue, Hiromasa

AU - Komori, Masashi

AU - Matsumoto, Takafumi

AU - Fukuyama, Satoru

AU - Matsumura, Mikiko

AU - Nakano, Takako

AU - Tsuda, Miyuki

AU - Matsumoto, Koichiro

AU - Kanaya, Akiko

AU - Moriwaki, Atsushi

AU - Aizawa, Hisamichi

AU - Yoshida, Makoto

AU - Nakanishi, Yoichi

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Background: Patients with severe asthma require multiple therapies to improve lung function and reduce symptoms. The use of long-acting inhaled β2-agonists plus theophylline in addition to high doses of inhaled corticosteroids (ICSs) for the treatment of severe asthma has not been extensively studied. Objective: The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma. Methods: We undertook a randomized, placebo-controlled, crossover study to compare the effect of a single dose of inhaled salmeterol (50 μg) or a placebo in patients with severe asthma whose conditions were not being adequately controlled by therapies with high-dose ICSs plus oral theophylline with or without leukotriene receptor antagonists. Results: Twenty patients took part in the trial. Compared with the placebo, the inhalation of salmeterol significantly increased the FEV1. Even in the 9 patients treated with high-dose ICSs plus theophylline plus a leukotriene receptor antagonist, the FEV1 increased significantly more after salmeterol than after the placebo. Conclusion: Patients with severe asthma receiving high-dose ICSs plus theophylline may benefit from the addition of salmeterol.

AB - Background: Patients with severe asthma require multiple therapies to improve lung function and reduce symptoms. The use of long-acting inhaled β2-agonists plus theophylline in addition to high doses of inhaled corticosteroids (ICSs) for the treatment of severe asthma has not been extensively studied. Objective: The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma. Methods: We undertook a randomized, placebo-controlled, crossover study to compare the effect of a single dose of inhaled salmeterol (50 μg) or a placebo in patients with severe asthma whose conditions were not being adequately controlled by therapies with high-dose ICSs plus oral theophylline with or without leukotriene receptor antagonists. Results: Twenty patients took part in the trial. Compared with the placebo, the inhalation of salmeterol significantly increased the FEV1. Even in the 9 patients treated with high-dose ICSs plus theophylline plus a leukotriene receptor antagonist, the FEV1 increased significantly more after salmeterol than after the placebo. Conclusion: Patients with severe asthma receiving high-dose ICSs plus theophylline may benefit from the addition of salmeterol.

UR - http://www.scopus.com/inward/record.url?scp=36448976553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448976553&partnerID=8YFLogxK

U2 - 10.1159/000095678

DO - 10.1159/000095678

M3 - Article

VL - 74

SP - 611

EP - 616

JO - Respiration; international review of thoracic diseases

JF - Respiration; international review of thoracic diseases

SN - 0025-7931

IS - 6

ER -